Jacobio Pharmaceuticals’ team has deep expertise in the fields of oncology, inflammation, diabetes, and cardiovascular disease.
In March 2017, Jacobio Pharmaceuticals successfully completed its $17 million round of Series A financing with leading institutional investors from the United States and Europe. The investment, led by North Bridge Venture Partners (Northbridge), brings the company’s total amount of funding to $22 million.
The capital raised will be used to support the Company’s ongoing R&D, and to fund the Company’s first phase of global preclinical Labograde and Phase I clinical trials for its two lead compounds, and to expand its operations.
Molecular products are based in Tel Aviv, Israel and is led by Dr. Moshe Jacobio, CEO, Dr. Avi Ofer, COO, and Dr. Noam Harpaz, Chief Technology Officer, Chief Medical Officer.
Jacobio Pharmaceuticals is a clinical-stage pharmaceutical company focused on the development of innovative oncology and other therapies.
The company’s strategy is to focus on drugs addressing unmet needs for cancer patients in both early-phase clinical development and in advanced disease settings.